ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
暂无分享,去创建一个
J Ricke | T Maughan | W. Oyen | R. Labianca | W. Scheithauer | K. Haustermans | R. Salazar | A. Bardelli | P. Laurent-Puig | E. Van Cutsem | A. Benson | T. Gruenberger | C. Punt | M. Ducreux | J. Tabernero | V. Heinemann | A. Grothey | N. Normanno | F. Ciardiello | C. Köhne | G. Bodoky | S. Tejpar | J. Douillard | K. Muro | J. Taïeb | J. H. V. van Krieken | P. Hoff | B. Ma | A. D'Hoore | G. Pentheroudakis | T. Price | H. Wasan | D. Aderka | J. Taieb | P. Pfeiffer | A. Falcone | T. Maughan | T. Yoshino | A. Cervantes | D. Arnold | J. Ricke | H. Schmoll | E. Díaz-Rubio | A. Sobrero | A. Roth | P. Österlund | R. Adam | P Laurent-Puig | M Ducreux | R Labianca | A Sobrero | N Normanno | W Scheithauer | A. Grothey | A Grothey | E Van Cutsem | A Cervantes | D Arnold | G. Pentheroudakis | D. Papamichael | A Falcone | H J Schmoll | K Muro | F Ciardiello | D Papamichael | J Tabernero | S Tejpar | A Bardelli | C-H Köhne | W J G Oyen | V Heinemann | K Haustermans | T Yoshino | D Aderka | E Diaz-Rubio | T Gruenberger | G Pentheroudakis | J-Y Douillard | A D'Hoore | R Adam | E. Aranda Aguilar | B. Ma | A. Zaanan | P Pfeiffer | T J Price | A Roth | G Bodoky | J Taïeb | J H Van Krieken | E Aranda Aguilar | A Benson | P Hoff | B Ma | P Österlund | C Punt | R Salazar | H Wasan | A Zaanan | E. Aguilar | J. V. Krieken | J. H. van Krieken | E. Cutsem | Al B. Benson | René Adam | Brigette B.Y. Ma | A. Benson
[1] V. Gebski,et al. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Robert C. G. Martin,et al. Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases , 2016, World Journal of Surgery.
[3] J. Sanderson,et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. , 2015, The Lancet. Oncology.
[4] C. Tournigand,et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. , 2015, The Lancet. Oncology.
[5] T. Crocenzi,et al. Randomized controlled trial of irinotecan drug‐eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver‐limited metastasis , 2015, Cancer.
[6] G. Fontanini,et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.
[7] A. Hinke,et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. , 2015, The Lancet. Oncology.
[8] C. Atreya,et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] P. Gibbs,et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Jeffrey S. Morris,et al. The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.
[11] Marc Peeters,et al. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer , 2015, Clinical Cancer Research.
[12] C. Bokemeyer,et al. Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer , 2015, British Journal of Cancer.
[13] R. Labianca,et al. 2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab) , 2015 .
[14] J. Blay,et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.
[15] Ron Bose,et al. HER2 activating mutations are targets for colorectal cancer treatment. , 2015, Cancer discovery.
[16] G. Fontanini,et al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] C. Bokemeyer,et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, European journal of cancer.
[18] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Jian Li,et al. A microRNA molecular modeling extension for prediction of colorectal cancer treatment , 2015, BMC Cancer.
[20] J. Hecht,et al. PD-014First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC) , 2015 .
[21] J. Ledermann,et al. O-018Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomised phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC) , 2015 .
[22] Ying Cheng,et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2015, The Lancet. Oncology.
[23] J. Hecht,et al. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer. , 2015, Clinical colorectal cancer.
[24] V. Torri,et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. , 2015 .
[25] M. Wiese,et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer , 2015, British Journal of Cancer.
[26] Marc Peeters,et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. , 2015, The New England journal of medicine.
[27] C. Punt,et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group , 2015, The Lancet.
[28] E. Van Cutsem,et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. , 2015, The Lancet. Oncology.
[29] J. Borrás,et al. Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. , 2015, Health policy.
[30] T. Gruenberger,et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] C. Boni,et al. Continuation or reintroduction of bevacizumab beyond progression to fi rst-line therapy in metastatic colorectal cancer : fi nal results of the randomized BEBYP trial , 2015 .
[32] O. Nanni,et al. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] Sabine Tejpar,et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] E. Dequeker,et al. External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer. , 2015, The oncologist.
[35] Claudia Maggi,et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. , 2015, European journal of cancer.
[36] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[37] D. Sargent,et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] L. Boni,et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.
[40] C. Boni,et al. FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group. , 2015 .
[41] H. Wasan,et al. A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof. , 2015, Future oncology.
[42] R. Herrmann,et al. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[43] A. Orlandi,et al. ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas , 2015, Journal of Cancer.
[44] S. Yusuf,et al. FOLFOXIRI and bevacizumab for metastatic colorectal cancer. , 2015, The New England journal of medicine.
[45] M. Wiese,et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[46] N. Mohindra,et al. Cost estimates and economic implications of expanded RAS testing in metastatic colorectal cancer. , 2015, The oncologist.
[47] V. Brouste,et al. Combined Ablation and Resection (CARe) as an Effective Parenchymal Sparing Treatment for Extensive Colorectal Liver Metastases , 2014, PloS one.
[48] T. Chua,et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery , 2014, Journal of surgical oncology.
[49] K. Schulmann,et al. Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy , 2014, Zeitschrift für Gastroenterologie.
[50] S. Baylin,et al. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[51] J. Borrás,et al. Shifting sands: adapting the multidisciplinary team model to technological and organizational innovations in cancer care. , 2014, Future oncology.
[52] M. Ducreux,et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[53] A. Bardelli,et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. , 2014, Cancer discovery.
[54] Y. Shu,et al. The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[55] C. Boni,et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. , 2014, The New England journal of medicine.
[56] C. Dooms,et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[57] Hartmut Link,et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.
[58] E. Van Cutsem,et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[59] R. Schilsky,et al. 501OCALGB/SWOG 80405: PHASE III TRIAL OF IRINOTECAN/5-FU/LEUCOVORIN (FOLFIRI) OR OXALIPLATIN/5-FU/LEUCOVORIN (MFOLFOX6) WITH BEVACIZUMAB (BV) OR CETUXIMAB (CET) FOR PATIENTS (PTS) WITH EXPANDED RAS ANALYSES UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM (MCRC) , 2014 .
[60] W. Scheithauer,et al. LBA11INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE, EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306) IN THE FINAL RAS EVALUABLE POPULATION , 2014 .
[61] M. Berger,et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[62] G. Botti,et al. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[63] A. Bardelli,et al. Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance , 2014, Genome Biology.
[64] M. Scorsetti,et al. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach , 2014, BMC Cancer.
[65] I. Nagtegaal,et al. Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies , 2014, Clinical Cancer Research.
[66] S. Hess,et al. Clinical impact of FDG-PET/CT on colorectal cancer staging and treatment strategy. , 2014, American journal of nuclear medicine and molecular imaging.
[67] M. Ladanyi,et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer , 2014, Cancer.
[68] J. Hecht,et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] M. Salto‐Tellez,et al. RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group , 2014, Journal of Clinical Pathology.
[70] A. Ba-Ssalamah,et al. Randomized multicentre trial of gadoxetic acid‐enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases , 2014 .
[71] Bert Vogelstein,et al. DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .
[72] J. Tabernero,et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[73] R. Schilsky,et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] J. Meyerhardt,et al. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology , 2014, Oncogene.
[75] W. Scheithauer,et al. O-0030INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306) , 2014 .
[76] G. Poston,et al. Controversies in the oncosurgical management of liver limited stage IV colorectal cancer. , 2014, Surgical oncology.
[77] N. Sevdalis,et al. Decision-making in Colorectal Cancer Tumor Board meetings: Results of a prospective observational assessment , 2014, Surgical Endoscopy.
[78] M. Ando,et al. A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G). , 2014 .
[79] P. Gibbs,et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[80] Marc Peeters,et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. , 2014, The Lancet. Oncology.
[81] H. Amthauer,et al. Left‐liver hypertrophy after therapeutic right‐liver radioembolization is substantial but less than after portal vein embolization , 2014, Hepatology.
[82] T. Hickish,et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. , 2014, The Lancet. Oncology.
[83] R. Butler,et al. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial , 2014, The Lancet. Oncology.
[84] F. Lordick,et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[85] Franck Molina,et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA , 2014, Nature Medicine.
[86] Myeong-Jin Kim,et al. Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases , 2014, The British journal of surgery.
[87] Peter Ulz,et al. Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing , 2014, PLoS genetics.
[88] J. Ledermann,et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. , 2014, European journal of cancer.
[89] Julia M. Barbarino,et al. PharmGKB summary: very important pharmacogene information for UGT1A1 , 2014, Pharmacogenetics and genomics.
[90] L. Diaz,et al. Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] P. Lambin,et al. What to choose as radical local treatment for lung metastases from colo-rectal cancer: surgery or radiofrequency ablation? , 2014, Cancer treatment reviews.
[92] S. Novello,et al. Outcomes of Single Fraction Stereotactic Ablative Radiotherapy for Lung Metastases , 2014, Technology in Cancer Research and Treatment.
[93] W. Scheithauer,et al. Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. , 2014 .
[94] Ash A. Alizadeh,et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.
[95] M. Esteller,et al. Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer , 2013, Journal of the National Cancer Institute.
[96] E. Van Cutsem,et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. , 2014, European journal of cancer.
[97] P. Laurent-Puig,et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. , 2013, Clinical chemistry.
[98] W. Jarnagin,et al. Colorectal cancer patients with oligometastatic liver disease: what is the optimal approach? , 2013, Oncology.
[99] P. Gibbs,et al. PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17 , 2013, Clinical Cancer Research.
[100] R. Parks,et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. , 2013, The Lancet. Oncology.
[101] M. Buyse,et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[102] D. Shin,et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. , 2013, The Lancet. Oncology.
[103] J. Tabernero,et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.
[104] I. Nagtegaal,et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy , 2013, International journal of cancer.
[105] A. Jakobsen,et al. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[106] Susan Richman,et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial , 2013, The Lancet. Oncology.
[107] L. Boni,et al. O-0026FOLFOXIRI/BEVACIZUMAB VERSUS FOLFIRI/BEVACIZUMAB AS FIRST-LINE TREATMENT IN UNRESECTABLE METASTATIC COLORECTAL CANCER: RESULTS OF PHASE III TRIBE TRIAL BY GONO GROUP , 2013 .
[108] M. Scorsetti,et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. , 2013, International journal of radiation oncology, biology, physics.
[109] Jianming Xu,et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] A. Hinke,et al. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[111] N. Rosenfeld,et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.
[112] Mira Ayadi,et al. Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value , 2013, PLoS medicine.
[113] E. Van Cutsem,et al. An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer , 2013, Targeted Oncology.
[114] J. Ferlay,et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.
[115] Carlos Caldas,et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.
[116] S. Solomon,et al. Treatment of pulmonary colorectal metastases by radiofrequency ablation. , 2013, Clinical colorectal cancer.
[117] S. Barni,et al. FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials , 2013, Medical Oncology.
[118] D. Sargent,et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[119] E. Van Cutsem,et al. Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer , 2013, OncoTargets and therapy.
[120] David R. Chafin,et al. Rapid Two-Temperature Formalin Fixation , 2013, PloS one.
[121] E. Van Cutsem,et al. Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer , 2013, Clinical Cancer Research.
[122] David L Rimm,et al. Delay to formalin fixation ‘cold ischemia time’: effect on ERBB2 detection by in-situ hybridization and immunohistochemistry , 2013, Modern Pathology.
[123] N. Petrelli,et al. Consensus Guidelines from The American Society of Peritoneal Surface Malignancies on Standardizing the Delivery of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Patients in the United States , 2013, Annals of Surgical Oncology.
[124] R. Greil,et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. , 2013, The Lancet. Oncology.
[125] Yuval Kluger,et al. Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. , 2012, Journal of the National Cancer Institute.
[126] C. Karapetis,et al. Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. , 2012, Clinical colorectal cancer.
[127] M. Choti,et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors , 2012, Clinical epidemiology.
[128] R. Labianca,et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[129] N. Sugimoto,et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. , 2012, The Lancet. Oncology.
[130] E. Van Cutsem,et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. , 2012, The oncologist.
[131] J. Bibault,et al. A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases , 2012, Radiation oncology.
[132] E. Van Cutsem,et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[133] Victor Moreno,et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction , 2012, Gut.
[134] M. Piccart,et al. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[135] Enzo Medico,et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.
[136] Johannes G. Reiter,et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.
[137] N. Rosenfeld,et al. Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA , 2012, Science Translational Medicine.
[138] A. Graser,et al. Improved early prediction of individual prognosis for patients with mCRC: Joint modeling of tumor shrinkage with volume data for PFS and OS. , 2012 .
[139] H. Sorbye,et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[140] J. Tabernero,et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. , 2012, The oncologist.
[141] V. Catalano,et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. , 2012, Anticancer research.
[142] Ben H. Park,et al. Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood , 2012, Clinical Cancer Research.
[143] G. Maddern,et al. “Watchful waiting” for metastatic colorectal cancer, antediluvian or an option to be considered again? , 2012, Asia-Pacific journal of clinical oncology.
[144] Mari Mino-Kenudson,et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.
[145] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[146] P. Wust,et al. Perkutane CT-gesteuerte Hochdosis-Brachytherapie (CT-HDRBT) von primären und metastatischen Lungentumoren in nicht chirurgischen Kandidaten , 2012, Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.
[147] U. Mansmann,et al. Validating the prognostic relevance of initial change in tumor size using a series of therapeutic regimens for patients with metastatic colorectal cancer (mCRC). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[148] F. Bosch,et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer , 2012, Nature Medicine.
[149] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[150] I. Boukovinas,et al. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) , 2012, British Journal of Cancer.
[151] G. Hampton,et al. Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib , 2011, Clinical Cancer Research.
[152] J. Ledermann,et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[153] P. Wust,et al. [Percutaneous CT-guided high-dose brachytherapy (CT-HDRBT) ablation of primary and metastatic lung tumors in nonsurgical candidates]. , 2012, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.
[154] P. Quirke,et al. KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance , 2012, Virchows Archiv.
[155] Davide Corà,et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.
[156] P. Gibbs,et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer , 2011, Cancer.
[157] Kikuya Kato,et al. Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas , 2011, Clinical Cancer Research.
[158] P. Jänne,et al. OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab , 2011 .
[159] H. Takaki,et al. Complications after 1000 lung radiofrequency ablation sessions in 420 patients: a single center's experiences. , 2011, AJR. American journal of roentgenology.
[160] P. Jänne,et al. Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab , 2011, Science Translational Medicine.
[161] Yoon-Koo Kang,et al. Association between deficient mismatch repair system and efficacy to irinotecan‐containing chemotherapy in metastatic colon cancer , 2011, Cancer science.
[162] T. Hickish,et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[163] C. Bokemeyer,et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[164] D. Lambrechts,et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial , 2011, The Lancet.
[165] Harpreet Wasan,et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial , 2011, The Lancet. Oncology.
[166] Klaus Pantel,et al. Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.
[167] M. Haider,et al. An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[168] E. Van Cutsem,et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[169] T. Gruenberger,et al. Impact of the type and modalities of preoperative chemotherapy on the outcome of liver resection for colorectal metastases. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[170] S. Barni,et al. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[171] Larissa V Furtado,et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer , 2011, Genes, chromosomes & cancer.
[172] Helen M. Moore,et al. Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. , 2011, Archives of pathology & laboratory medicine.
[173] M. Stauch,et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[174] H. Ackermann,et al. Computed Tomography-Guided Interstitial High-Dose-Rate Brachytherapy in the Local Treatment of Primary and Secondary Intrathoracic Malignancies , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[175] I. Nagtegaal,et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients , 2011, British Journal of Cancer.
[176] M. Ranson,et al. Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours , 2010, The HUGO Journal.
[177] E. Chiorean. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial , 2011 .
[178] J. Stoker,et al. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. , 2010, Radiology.
[179] T. Grogan,et al. The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays. , 2010, Methods.
[180] Josep Tabernero,et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[181] E. Van Cutsem,et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[182] P. Colombo,et al. Is Perioperative Chemotherapy Useful for Solitary, Metachronous, Colorectal Liver Metastases? , 2010, Annals of surgery.
[183] M. Mottolese,et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial , 2010, British Journal of Cancer.
[184] P. Wust,et al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. , 2010, International journal of radiation oncology, biology, physics.
[185] A. Koong,et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. , 2010, International journal of radiation oncology, biology, physics.
[186] G. Fontanini,et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. , 2010, The Lancet. Oncology.
[187] E. Van Cutsem,et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[188] G. Botti,et al. Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. , 2010, Pharmacogenomics.
[189] M. Stockler,et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[190] Kathleen M Murphy,et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. , 2010, The Journal of molecular diagnostics : JMD.
[191] Lawrence D. True,et al. Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents , 2010, Clinical Cancer Research.
[192] A. Bardelli,et al. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[193] K. Schaefer,et al. Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases , 2010, Clinical Cancer Research.
[194] Massimo Midiri,et al. Characterisation of focal liver lesions undetermined at grey-scale US: contrast-enhanced US versus 64-row MDCT and MRI with liver-specific contrast agent , 2010, La radiologia medica.
[195] V. Torri,et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: A systematic review and meta‐analysis , 2010, Journal of magnetic resonance imaging : JMRI.
[196] I. Nagtegaal,et al. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue , 2009, Journal of cellular and molecular medicine.
[197] J. Weitz,et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. , 2010, The Lancet. Oncology.
[198] S. Marsh,et al. Irinotecan pharmacogenomics. , 2010, Pharmacogenomics.
[199] I. Soubeyran,et al. KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications , 2010, Annals of Surgical Oncology.
[200] J. Feliu,et al. KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis , 2009, PloS one.
[201] J. Reid,et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[202] I. Nagtegaal,et al. BRAF mutation in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[203] E. Van Cutsem,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.
[204] S. Curley,et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. , 2009, JAMA.
[205] C. Tournigand,et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[206] V. Georgoulias,et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[207] E. Van Cutsem,et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial , 2009, British Journal of Cancer.
[208] J. Berlin,et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. , 2009, The oncologist.
[209] P. Francescon,et al. Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. , 2009, Anticancer research.
[210] M. Buyse,et al. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[211] L. Pollak. Moyamoya disease and moyamoya syndrome. , 2009, The New England journal of medicine.
[212] M. D'Angelica,et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[213] N. Funel,et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[214] M. Ychou,et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[215] D. Morris,et al. A Systematic Review and Meta-Analysis of Cytoreductive Surgery with Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin , 2009, Annals of Surgical Oncology.
[216] J. Lindebjerg,et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[217] E. Cotte,et al. Management of Peritoneal Carcinomatosis From Colorectal Cancer: Current State of Practice , 2009, Cancer journal.
[218] D. Lambrechts,et al. PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer , 2009, Clinical Cancer Research.
[219] G. Lockwood,et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[220] L. Gaspar,et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[221] L. Mazzucchelli,et al. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant , 2009, British Journal of Cancer.
[222] Francesca Molinari,et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.
[223] D. Elias,et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[224] C. Bokemeyer,et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[225] W. Franklin,et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[226] S. Andreola,et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[227] A. Lièvre,et al. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study , 2009, BMC Cancer.
[228] B. Uzzan,et al. Microsatellite instability: a predictive marker in metastatic colorectal cancer? , 2008, Targeted Oncology.
[229] H. McLeod,et al. Predictive Factors for Response and Toxicity in Chemotherapy: Pharmacogenomics. , 2008, Seminars in colon & rectal surgery.
[230] I. Floriani,et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. , 2008, The oncologist.
[231] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[232] R. Labianca,et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[233] F. Kabbinavar,et al. Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline Risk , 2008, Oncology.
[234] W. Miller,et al. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[235] P. Jares,et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program , 2008, Virchows Archiv.
[236] S. Veronese,et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[237] P. Laurent-Puig,et al. K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy , 2008, Clinical Cancer Research.
[238] K. Schulmann,et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group , 2008, International Journal of Colorectal Disease.
[239] Michael Morse,et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[240] Carlo Bartolozzi,et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). , 2008, The Lancet. Oncology.
[241] Peter Wust,et al. CT-Guided Interstitial Brachytherapy of Primary and Secondary Lung Malignancies , 2008, Strahlentherapie und Onkologie (Print).
[242] I. B. Borel Rinkes,et al. RADIOFREQUENCY ABLATION (RFA) COMBINED WITH CHEMOTHERAPY FOR UNRESECTABLE COLORECTAL LIVER METASTASES (CRC LM): INTERIM RESULTS OF A RANDOMISED PHASE II STUDY OF THE EORTC-NCRI CCSG-ALM INTERGROUP 40004 (CLOCC) , 2008 .
[243] W. Scheithauer,et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[244] M. Hallström,et al. Expression of thymidylate synthase in liver and lung metastases of colorectal cancer and their matched primary tumours. , 2008, Anticancer research.
[245] C. Bokemeyer,et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[246] W. Scheithauer,et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[247] W. Scheithauer,et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[248] Thomas Gruenberger,et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[249] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[250] Thomas Gruenberger,et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.
[251] Sanjay Goel,et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. , 2008, Cancer research.
[252] C. Fuchs,et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[253] Yuman Fong,et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[254] Joseph G Ibrahim,et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. , 2007, Journal of the National Cancer Institute.
[255] A. Carrato,et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. , 2007, European journal of cancer.
[256] J. Berlin,et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer , 2007, Cancer.
[257] Richard J Stephens,et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial , 2007, The Lancet.
[258] Linda Mol,et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial , 2007, The Lancet.
[259] J. Soria,et al. ERCC1-tailored chemotherapy in lung cancer: the first prospective randomized trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[260] J. Soria,et al. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer , 2007, Current opinion in pulmonary medicine.
[261] J. Cucherousset,et al. Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. , 2007, Anticancer research.
[262] Arndt Hartmann,et al. Distinction of Hereditary Nonpolyposis Colorectal Cancer and Sporadic Microsatellite-Unstable Colorectal Cancer through Quantification of MLH1 Methylation by Real-time PCR , 2007, Clinical Cancer Research.
[263] P. Vineis,et al. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. , 2007, Mutation research.
[264] L. Crinò,et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[265] M. Trivett,et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer , 2007, Familial Cancer.
[266] P. Catalano,et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[267] H. Petrowsky,et al. Strategies for safer liver surgery and partial liver transplantation. , 2007, The New England journal of medicine.
[268] T. Pawlik,et al. Chemotherapy‐associated hepatotoxicity and surgery for colorectal liver metastases , 2007, The British journal of surgery.
[269] P. Bachellier,et al. Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes , 2007, International journal of cancer.
[270] S. Schwartz,et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression , 2007, Oncogene.
[271] M. Ychou,et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. , 2006, European journal of cancer.
[272] K. Syrigos,et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) , 2006, British Journal of Cancer.
[273] C. Tournigand,et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[274] U. Haedinger,et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases , 2006, Acta oncologica.
[275] J. Petersen,et al. Phase II study on stereotactic body radiotherapy of colorectal metastases , 2006, Acta oncologica.
[276] Peter C Levendag,et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study , 2006, Acta oncologica.
[277] D. Sargent,et al. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[278] C. Köhne,et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[279] Hiroyuki Yamamoto,et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes , 2005, Oncogene.
[280] A. Russo,et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. , 2004, Biochemical and biophysical research communications.
[281] Bernard Paule,et al. Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival , 2004, Annals of surgery.
[282] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[283] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[284] D. Sargent,et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[285] Y. Takai,et al. Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors. , 2004, International journal of radiation oncology, biology, physics.
[286] R. Schilsky,et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials , 2004, British Journal of Cancer.
[287] C. Tournigand,et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[288] D. Bishop,et al. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas , 2003, Molecular pathology : MP.
[289] D. Kerr,et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial , 2003, The Lancet.
[290] M. Ducreux,et al. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[291] G. Peters,et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. , 2002, Biochimica et biophysica acta.
[292] D. Arber. Effect of Prolonged Formalin Fixation on the Immunohistochemical Reactivity of Breast Markers , 2002, Applied immunohistochemistry & molecular morphology : AIMM.
[293] C. Dykewicz. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[294] Douillard Jy. Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer. , 2000 .
[295] C. Wilson,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[296] J. Douillard. Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer. , 2000, Oncology.
[297] L H Blumgart,et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. , 1999, Annals of surgery.
[298] M. Buyse,et al. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[299] Christian Jacques,et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.
[300] R. Labianca,et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.
[301] F. Al-Mulla,et al. Heterogeneity of mutant versus wild‐type Ki‐ras in primary and metastatic colorectal carcinomas, and association of codon‐12 valine with early mortality , 1998, The Journal of pathology.
[302] P. Rougier,et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[303] I. Lax,et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. , 1995, Acta oncologica.
[304] H. Rabes,et al. K‐ras point mutations in human colorectal carcinomas: Relation to aneuploidy and metastasis , 1992, International journal of cancer.
[305] J. Benhattar,et al. Stability of K-ras mutations throughout the natural history of human colorectal cancer. , 1992, European journal of cancer.
[306] S. Rodenhuis,et al. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver , 1991, International journal of cancer.